CMA
AZN icon

Cedar Mountain Advisors’s AstraZeneca AZN Stock Holding History

Cedar Mountain Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.6K Sell
19
-6
-24% -$1.13K ﹤0.01% 773
2026
Q1 		$4.93K Buy
25
+2
+9% +$386 ﹤0.01% 661
2025
Q4 		$4.14K Buy
23
+16
+229% +$2.81K ﹤0.01% 334
2025
Q3 		$997 Buy
+7
New +$1.06K ﹤0.01% 531

Other funds holding AZN

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return
CAM
Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
MIM
Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Cedar Mountain Advisors's AZN Position: Q2 2026 in Review

Cedar Mountain Advisors reduced its AstraZeneca (AZN) stake by 24% in Q2 2026, selling an estimated $1.13K and leaving 19 shares worth $3.6K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Cedar Mountain Advisors first reported a position in AZN in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.93K in Q1 2026. 233 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Cedar Mountain Advisors held 19 shares of AstraZeneca worth $3.6K as of Q2 2026.
  • Cedar Mountain Advisors sold 6 AstraZeneca shares in Q2 2026, an estimated $1.13K.
  • AstraZeneca made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #773 holding.
  • Cedar Mountain Advisors first reported a position in AstraZeneca in Q3 2025 and has held it in 4 quarters since.
  • Cedar Mountain Advisors's AstraZeneca position peaked at $4.93K in Q1 2026.
  • 233 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.